Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • For patients with multiple PI-associated metabolic toxicities, substitution of the PI by an NNRTI or integrase inhibitor may be justified, assuming the switch would not result in loss of virologic control (Table 10)[Martínez 2000]

Action required